title: [Biofilm formation by strains of Burkholderia cepacia complex in dependence of their phenotypic and genotypic characteristics].
abstract: Biofilm formation was studied in 54 strains of Burkholderia cepacia complex isolated in 7 Moscow hospitals. 80% of strains (biofilm groups I and II) had the capacity to biofilm formation and only 16.7% of strains (group III) were not capable to biofilm formation. Molecular genetic methods allowed to identify one of the epidemic markers (CBL, IS hybrid sequence, Burkholderia Cepacia Epidemic Strain Marker - BCESM) in 46.7, 23.3, and 33.3% of strains from group I, II, and III respectively. Gene cepR from the Quorum Sensing system was identified in three biofilm groups in nearly equal frequency (92.3, 96.2 and 100% for group I, II, and III respectively), whereas cepl gene was found more often in group I (76.9%) and II (65.4%). Strains from all three groups had protease and lipase activity and 13.3% of group I strains had chitinolytic activity. B. cepacia strains from group I produced hemolysin in 33.3% of cases, from group II--in 26.6%, and from group III--in 11.1% of cases. The majority of Moscow hospital strains of B. cepacia complex were identified as B. cenocepacia (genomovar III, group A). RAPD-PCR method enabled to differentiate isolated strains into several genotypic variants. 13.3% of strains from group I were susceptible to imipenem/ciprofloxacin, as well as 33.3% of isolates from group II and 44.4% of isolates from group III.
authors.forename: I A
authors.initials: IA
authors.lastname: Shaginian
authors.forename: G A
authors.initials: GA
authors.lastname: Danilina
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Chernukha
authors.forename: G V
authors.initials: GV
authors.lastname: Alekseeva
authors.forename: A B
authors.initials: AB
authors.lastname: Batov
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics; D018441:Biofilms / Q000254:growth & development*; D015415:Biomarkers; D019121:Burkholderia Infections / Q000382:microbiology; D042602:Burkholderia cepacia complex / Q000145:classification / Q000187:drug effects / Q000502:physiology*; D002939:Ciprofloxacin / Q000494:pharmacology; D029968:Escherichia coli Proteins / Q000235:genetics; D006460:Hemolysin Proteins / Q000378:metabolism; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D008025:Ligases / Q000235:genetics; D008049:Lipase / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D009031:Moscow; D010447:Peptide Hydrolases / Q000378:metabolism; D019105:Random Amplified Polymorphic DNA Technique; D013045:Species Specificity; D014157:Transcription Factors / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D015415:Biomarkers; C097229:Cbl protein, E coli; C117246:CepR protein, Burkholderia; D029968:Escherichia coli Proteins; D006460:Hemolysin Proteins; D014157:Transcription Factors; D002939:Ciprofloxacin; D015378:Imipenem; D008049:Lipase; D010447:Peptide Hydrolases; D008025:Ligases; C449816:N-acylhomoserine lactone synthase